A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent, in Combination with CPI-444, and in Combination with Pembrolizumab in Adult Subjects with Advanced Cancers

Protocol No
CORVUS-CPI-006-001
Principal Investigator
Matthew Riese
Phase
I
Summary
If you agree to take part in this study and you are eligible for participation, you will be assigned into one of three treatment groups by the Sponsor or designee: 1. CPI-006 Intravenous (IV) injection 2. CPI-006 Intravenous (IV) injection + CPI-444 (oral) 3. CPI-006 Intravenous (IV) injection + pembrolizumab Intravenous (IV) The chances of you being assigned to any treatment group will depend upon which groups are open during your participation in the study. You or the study doctor will not be able to choose which treatment group you will be able to participate in, and you will remain on the same treatment group for your entire study participation.
Description
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: